Lafora disease, a severe form of epilepsy, is a genetically transmitted condition. It typically begins with epileptic seizures in late childhood or adolescence and has a progressive course. Lafora disease is characterized by symptoms such as sudden jerks and irregular muscle contractions, temporary blindness, visual illusions, walking difficulties, loss of balance, and speech disorders.

Unfortunately, there is currently no treatment that will completely eliminate Lafora disease. However, treatments generally aim to control epileptic seizures and improve patient functionality. Lafora disease is a rare inherited neurometabolic disorder among progressive myoclonic epilepsy syndromes.

This disease occurs when substances called Lafora bodies accumulate in organs such as the nervous system, heart, liver, and sweat glands due to a defect in carbohydrate metabolism. The disease usually appears in late childhood and adolescence and can affect both sexes equally. Clinically, symptoms include epileptic seizures, myoclonus (involuntary muscle movements), and cognitive decline.

Lafora disease is a progressive disease and currently its treatment is only aimed at relieving symptoms and improving the patient's quality of life.

Causes of Lafora disease

Lafora disease is a genetic disorder transmitted as an autosomal recessive trait. Mutations in the EPM2A and NHLRC1 genes are responsible for its development. Mutations in these genes disrupt carbohydrate metabolism and lead to abnormal glycogen accumulation in cells. This accumulation leads to the accumulation of abnormal substances called Lafora bodies within the cells.

This abnormal accumulation in cells can disrupt their normal functioning and, over time, cause problems with cellular function. Lafora bodies can contribute to the symptoms of the disease by preventing cells from functioning properly. This can trigger epileptic seizures, myoclonus, and other symptoms of the disease. Therefore, Lafora disease is often associated with mutations in these genes and is associated with disorders in carbohydrate metabolism.

Lafora disease symptoms

Symptoms of Lafora disease generally do not appear in the first 10 years of life, when physical and mental development is normal. However, some patients may have a history of epileptic seizures in early childhood. In most patients, seizures begin between the ages of 12 and 17.

Symptoms of Lafora disease include a type of seizure called "generalized tonic-clonic seizure" with widespread contractions throughout the body, myoclonic seizures with sudden and irregular muscle jerks, and occipital seizures accompanied by temporary blindness and visual hallucinations.

The severity and frequency of seizures increase over time and can become resistant to treatment. Motor skill problems, such as walking difficulties and loss of balance, may occur. This can lead to poor academic performance. Behavioral changes and speech disorders may also be observed. As the disease progresses, cognitive impairments may become more pronounced.

Lafora disease typically progresses over five to 10 years. Symptoms worsen over time, and as the disease progresses, the patient's quality of life can be significantly impacted.

How is Lafora disease diagnosed?

Lafora disease can be diagnosed using a variety of methods. These include clinical findings, electroencephalography ( EEG ), muscle and skin biopsies to identify inclusion bodies, also known as Lafora bodies, which are characteristic of Lafora disease, and genetic analysis.

Doctors assess the suspicion of Lafora disease based on the patient's symptoms and clinical findings. An EEG is a method used to examine brain activity and can aid in diagnosis by revealing specific patterns in the case of Lafora disease.

Muscle and skin biopsies are samples taken from body tissues. These biopsies can be examined to observe the characteristic Lafora bodies, particularly in Lafora disease. The presence of these bodies can be a key diagnostic finding.

Additionally, genetic analyses are performed to identify genetic mutations that cause the disease. Identifying mutations in the EPM2A and NHLRC1 genes is an important step in confirming the genetic origin of Lafora disease.

Diagnosis is usually made through a combination of these various methods, supported by the physician's clinical assessment. Such a multifaceted approach is crucial for establishing an accurate diagnosis of Lafora disease.

What is the treatment for Lafora disease?

Unfortunately, there is currently no specific treatment that completely eliminates Lafora disease. However, treatments generally aim to alleviate symptoms and improve quality of life. The focus of this disease is on controlling epileptic seizures and preserving functionality.

Depending on the type and characteristics of the epileptic seizures experienced by the patient, various medications and treatment methods can be used to treat them. These can help reduce the frequency of seizures or control them. It is also important for the patient to avoid situations in their daily lives that could trigger seizures, such as sleep deprivation, prolonged exposure to bright light, stress, or prolonged fasting.

Treatment is determined by the patient's individual situation, and there are currently no specific treatment options to slow the progression of the disease. However, a multidisciplinary approach is taken to control epileptic seizures and maintain the patient's overall health. This may include involvement of neurologists, nutritionists, and other specialists.

Treatment for Lafora disease focuses on relieving symptoms, improving the patient's quality of life, and reducing the effects of seizures. However, the course of the disease can vary from person to person, and the severity of symptoms can progress over time. Therefore, there is no specific treatment to slow the progression of the disease; instead, treatments focused on symptom management are generally used.

Risk factors for Lafora disease

Lafora disease is a genetic disorder transmitted in an autosomal recessive manner. This suggests that mutations in specific genes are involved in the development of the disease. Situations such as consanguineous marriages may promote the transmission of the same mutation and increase the frequency of this genetic disorder within the same family. Therefore, the likelihood of the disease occurring within families may increase.

However, because the risk of developing Lafora disease is generally genetic, a person's risk of developing the disease depends on the likelihood of the disease running in the family and the presence of certain gene mutations. A previous family history of the disease may increase the risk, but the exact likelihood of developing the disease cannot be determined.

Generally, risk factors for Lafora disease are based on factors such as the presence of these genetic mutations and a family history of the disease. Consanguineous marriages may increase the risk because they can increase the likelihood of the same genetic mutations, but how this affects the likelihood of developing the disease depends on the individual situation.

Are there any other diseases that can be confused with Lafora disease? 

Yes, Lafora disease can sometimes be confused with other conditions. Especially in its initial stages, it can be confused with benign epileptic seizures. For example, it can be confused with benign conditions like juvenile myoclonic epilepsy because they have similar ages of onset. However, there are differences between Lafora disease and these conditions. In Lafora disease, features such as EEG findings, resistance to antiepileptic drugs, the presence of other seizure types, cognitive impairment, and rapid progression of symptoms may suggest progressive myoclonic epilepsy.

Additionally, other conditions characterized by progressive myoclonic seizures can be confused with Lafora disease. For example, conditions such as Unverricht-Lundborg disease, neuronal ceroid lipofuscinosis, sialidosis, and mitochondrial encephalomyopathies can exhibit similar symptoms and be confused with Lafora disease. Distinguishing between these conditions is often achieved through clinical findings, as well as through testing, particularly genetic analysis. This is crucial for establishing a correct diagnosis and initiating appropriate treatment.

Should psychological and social support be sought in Lafora disease?

Yes, Lafora disease is a progressive condition that can be challenging for both the individual and their family or caregivers. In this case, psychological and social support is crucial.

Coping with a genetic condition like Lafora disease can be emotionally challenging for both the patient and their family. Emotional reactions to the disease include stress, anxiety, sadness, and confusion. In these cases, seeking psychological support can help both the patient and family cope with these emotional challenges. Providing emotional support through counseling or therapy can be beneficial.

Social support is also important. Joining support groups or connecting with others who are going through similar situations can be helpful in sharing experiences and gaining support.

Genetic counseling can provide information and guidance to families who have a family history of a condition like Lafora disease or are being considered carriers. This type of support can be both emotionally and informationally important and can facilitate coping with the disease.